145 related articles for article (PubMed ID: 35056740)
1. A "Double-Locked" and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy.
Luo J; Guan Z; Gao W; Wang C; Xu Z; Meng C; Liu Y; Zhang Y; Guo Q; Ling Y
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056740
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-triggered single molecule probe for high-contrast NIR II/PA tumor imaging and robust photothermal therapy.
Meng X; Zhang J; Sun Z; Zhou L; Deng G; Li S; Li W; Gong P; Cai L
Theranostics; 2018; 8(21):6025-6034. PubMed ID: 30613279
[TBL] [Abstract][Full Text] [Related]
4. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities.
Ling Y; Feng J; Luo L; Guo J; Peng Y; Wang T; Ge X; Xu Q; Wang X; Dai H; Zhang Y
ChemMedChem; 2017 May; 12(9):646-651. PubMed ID: 28425177
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
[TBL] [Abstract][Full Text] [Related]
8. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Payne JE; Jenkins DA; Bonnefous C; Trotter C; Wang Y; Anzola JV; Milkova EL; Hoffman TZ; Dozier SJ; Wiley BM; Saven A; Malecha JW; Davis RL; Muhammad J; Shiau AK; Noble SA; Rao TS; Smith ND; Hager JH
Mol Cancer Ther; 2008 May; 7(5):1054-65. PubMed ID: 18483295
[TBL] [Abstract][Full Text] [Related]
9. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor.
Kong Y; Jung M; Wang K; Grindrod S; Velena A; Lee SA; Dakshanamurthy S; Yang Y; Miessau M; Zheng C; Dritschilo A; Brown ML
Mol Cancer Ther; 2011 Sep; 10(9):1591-9. PubMed ID: 21697394
[TBL] [Abstract][Full Text] [Related]
11. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
[TBL] [Abstract][Full Text] [Related]
12. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Ling Y; Xu C; Luo L; Cao J; Feng J; Xue Y; Zhu Q; Ju C; Li F; Zhang Y; Zhang Y; Ling X
J Med Chem; 2015 Dec; 58(23):9214-27. PubMed ID: 26555243
[TBL] [Abstract][Full Text] [Related]
13. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
14. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
15. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
16. Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
Ling Y; Li Y; Zhu R; Qian J; Liu J; Gao W; Meng C; Miao J; Xiong B; Qiu X; Ling C; Dai H; Zhang Y
J Nat Prod; 2019 Jun; 82(6):1442-1450. PubMed ID: 31120744
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
Zang J; Liang X; Huang Y; Jia Y; Li X; Xu W; Chou CJ; Zhang Y
J Med Chem; 2018 Jun; 61(12):5304-5322. PubMed ID: 29787262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
